Circio Holding has presented preclinical data at ASGCT demonstrating that its circVec circular RNA platform achieved up to 40-fold greater gene expression in cardiac tissue and 50-fold in ocular ...

A novel circular RNA platform increased AAV-driven gene expression up to 50-fold, supporting efforts to improve safety, and ...

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Using circular RNA, we’ve developed a platform we call isCAR™ for the in vivo delivery of CARs to immune cells. RNA is transient, but circular RNA, compared to linear mRNA, persists much longer in ...

It's no secret that we need new ways to treat and detect disease, including cancer. Specifically, we need better biomarkers that can be used for diagnosis and better ways to selectively get medicine ...

Circular RNA (circRNA) is a unique type of non-coding RNA produced by back splicing of mRNA to form the covalent junction without 3’-5’ polarity and poly(A) tail. CircRNA was first discovered about 30 ...

It’s no secret that we need new ways to treat and detect disease, including cancer. Specifically, we need better biomarkers that can be used for diagnosis and better ways to selectively get medicine ...

The next generation RNA therapeutics market offers growth in RNA-based treatments, driven by innovations in platforms like saRNA, enhancing gene expression. Key opportunities lie in oncology and ...

The use of RNA is a promising approach for a growing range of therapeutics and vaccines, but overcoming a few challenges would enable it even further. Stability and persistence in the body are ...